Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 1;155(8):929-938.
doi: 10.1001/jamadermatol.2019.0696.

Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis

Ji Hae Lee  1 , Hyuck Sun Kwon  1 , Han Mi Jung  1 , Hyunyong Lee  2 , Gyong Moon Kim  1 , Hyeon Woo Yim  3 , Jung Min Bae  1
Affiliations

Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis

Ji Hae Lee et al. JAMA Dermatol. .

Abstract

Importance: Topical calcineurin inhibitors (TCIs), including tacrolimus and pimecrolimus, have been widely used for the treatment of vitiligo; however, the efficacy of TCI monotherapy is often underestimated.

Objectives: To estimate the treatment responses to both TCI monotherapy and TCI accompanied by phototherapy for vitiligo, based on relevant prospective studies, and to systematically review the mechanism of action of TCIs for vitiligo treatment.

Data sources: A comprehensive search of the MEDLINE, Embase, Web of Science and Cochrane Library databases from the date of database inception to August 6, 2018, was conducted. The main key words used were vitiligo, topical calcineurin inhibitor, tacrolimus, pimecrolimus, and FK506.

Study selection: Of 250 studies initially identified, the full texts of 102 articles were assessed for eligibility. A total of 56 studies were identified: 11 studies on the TCI mechanism, 36 studies on TCI monotherapy, 12 studies on TCI plus phototherapy, and 1 study on TCI maintenance therapy.

Data extraction and synthesis: Two reviewers independently extracted data on study design, patients, intervention characteristics, and outcomes. Random-effects meta-analyses using the generic inverse variance weighting were performed for the TCI monotherapy and TCI plus phototherapy groups.

Main outcomes and measures: The primary outcomes were the rates of at least mild (≥25%), at least moderate (≥50%), and marked (≥75%) repigmentation responses to treatment. These rates were calculated by dividing the number of participants in an individual study who showed the corresponding repigmentation by the total number of participants who completed that study.

Results: In the 56 studies included in the analysis, 46 (1499 patients) were selected to evaluate treatment response. For TCI monotherapy, an at least mild response was achieved in 55.0% (95% CI, 42.2%-67.8%) of 560 patients in 21 studies, an at least moderate response in 38.5% (95% CI, 28.2%-48.8%) of 619 patients in 23 studies, and a marked response in 18.1% (95% CI, 13.2%-23.1%) of 520 patients in 19 studies after median treatment duration of 3 months (range, 2-7 months). In the subgroup analyses, face and neck lesions showed an at least mild response in 73.1% (95% CI, 32.6-83.5%) of patients, and a marked response in 35.4% (95% CI, 24.9-46.0%) of patients. For TCI plus phototherapy, an at least mild response to TCI plus phototherapy was achieved in 89.5% (95% CI, 81.1-97.9%) of patients, and a marked response was achieved in 47.5% (95% CI, 30.6-64.4%) of patients.

Conclusions and relevance: The use of TCIs, both as a monotherapy and in combination with phototherapy, should be encouraged in patients with vitiligo.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.
Figure 1.. Flow Diagram Showing How Eligible Studies Were Identified
Figure 2.
Figure 2.. Treatment Response to Topical Calcineurin Inhibitors (TCIs) in Patients With Vitiligo
A, Treatment response to TCI monotherapy. B, Treatment response to TCI plus phototherapy.
See this image and copyright information in PMC

References

    1. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview—part I: introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473-491. doi:10.1016/j.jaad.2010.11.061 - DOI - PubMed
    1. Bae JM, Lee SC, Kim TH, et al. . Factors affecting quality of life in patients with vitiligo: a nationwide study. Br J Dermatol. 2018;178(1):238-244. doi:10.1111/bjd.15560 - DOI - PubMed
    1. Taieb A, Alomar A, Böhm M, et al. ; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Europénne des Médecins Spe´cialistes (UEMS) . Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5-19. doi:10.1111/j.1365-2133.2012.11197.x - DOI - PubMed
    1. Oiso N, Suzuki T, Wataya-Kaneda M, et al. . Guidelines for the diagnosis and treatment of vitiligo in Japan. J Dermatol. 2013;40(5):344-354. doi:10.1111/1346-8138.12099 - DOI - PubMed
    1. Bae JM, Hong BY, Lee JH, Lee JH, Kim GM. The efficacy of 308-nm excimer laser/light (EL) and topical agent combination therapy versus EL monotherapy for vitiligo: a systematic review and meta-analysis of randomized controlled trials (RCTs). J Am Acad Dermatol. 2016;74(5):907-915. doi:10.1016/j.jaad.2015.11.044 - DOI - PubMed